Gynecologic and Breast Cancers: What's New in Chemoresistance and Chemosensitivity Tests?

Curr Probl Cancer. 2023 Aug;47(4):100996. doi: 10.1016/j.currproblcancer.2023.100996. Epub 2023 Jul 8.


Gynecological and breast cancers affect women's health worldwide. Although chemotherapy is one of the principal treatments for cancer, it also has limitations owing to toxicity and tumor resistance to the drugs used. Thus, individualized treatment based on personal tumor characteristics is essential for improving therapeutic outcomes and patient survival. Chemoresistance and chemosensitivity tests can be useful for predicting tumor response and guiding chemotherapy choices. This methodology has already been applied to breast, ovarian, cervical, and endometrial cancers, identifying successfully which drugs cause resistance and sensitivity responses for each individual person, influencing their progression-free survival and overall response. In addition, more recent techniques, such as organoids and patient-derived xenografts, can also recapitulate patients' tumor characteristics and contribute to chemo response evaluation. Therefore, this review compiles information on chemoresistance and chemosensitivity tests performed in gynecologic and breast cancers and their main results for women's health improvement.

Keywords: Breast cancer; Chemoresistance; Chemosensitivity; Extreme drug resistance; Gynecologic cancer; Patient-derived xenograft; Personalized medicine.

Publication types

  • Review

MeSH terms

  • Breast
  • Breast Neoplasms* / drug therapy
  • Drug Resistance, Neoplasm
  • Endometrial Neoplasms*
  • Female
  • Gynecology*
  • Humans